Early-stage and mid-size bio/pharmaceutical companies have enjoyed an embarrassment of riches over the past 18 months.
Early-stage and mid-size bio/pharmaceutical companies have enjoyed an embarrassment of riches over the past 18 months. The window for initial public offerings (IPOs) re-opened, at least for a while. Global bio/pharmaceutical companies continued their frenzied pace of partnering and acquisition activity, and venture capital spiked up as the prospects improved for rich exits.
The results of the 2014 edition of the PharmSource/Pharmaceutical Technology Outsourcing Survey show that strong growth is continuing. See Jim Miller’s Pharmaceutical Technology article here.
This entry was posted in
PharmSource/Pharmaceutical Technology Outsourcing Survey
. Bookmark the
. Trackbacks are closed, but you can
post a comment